OBJECTIVES: To classify the characteristics and properties of the pharmacological treatments among migraine patients treated by neurologists in Spain. Patients are becoming increasingly implicated in treatment decisions. Expectations in relation to therapy largely condition satisfaction with the results obtained. METHODS: Multicenter, cross-sectional study in adult patients with at least one prescription of antimigraine drugs within the last year. The protocol was approved by the CREC of La Princesa University Hospital (Madrid). Sociodemographic, and clinical characteristics of patients, as well as questions regarding their expectations with regard to migraine treatments and evaluation of the importance of their attributes are documented. Using a treatment expectations questionnaire and applying Kano methodology, sixteen treatment attributes were classifi ed as: Must-be, One-dimensional, Attractive, Indifferent, Reverse or Questionable. Patients were required to give informed consent. RESULTS: 68 neurologists included 174 patients diagnosed with migraine (mean age 39 years; 75% women). None of the attributes were considered "Must-be". The attributes considered by most patients to be "One-dimensional" were the absence of long-term adverse effects (55%), to allow work/study activities (50%), to allow social and family relationship (50%), achievement of symptoms relief (47%) and pain relief (44.3%). The attributes considered "Attractive" by most patients were: achievement of rapid symptoms and pain relief (54%), and achievement of total disappearance of the pain (53.4%). The attributes that led to a greater dissatisfaction were the occurrence of long-term adverse effects, not to allow work activity or studies and not to achieve pain relief. The three attributes that led to a greater satisfaction were achievement of total disappearance of the symptoms and the pain, and rapid pain relief. CONCLU-SIONS: The expectations regarding a medical treatment signifi cantly infl uence the satisfaction reached with the outcome of such treatment. a better knowledge of patient's expectations can lead to a greater satisfaction associated with treatment outcomes.
PND48 MODIFIED LAST OBSERVATION CARRIED FORWARD IS A SUPERIOR METHOD OF IMPUTATION
DeGryse R, Lei X, Fainaru I, Turkel C Allergan, Inc., Irvine, CA, USA OBJECTIVES: To compare imputation methods using PREEMPT (Phase III REsearch Evaluating Migraine Prophylaxis Therapy) clinical data. METHODS: Data were analyzed from two phase 3 studies of onabotulinumtoxinA in chronic migraine (ICHD-II migraine and ≥15 headache days/month). Each study included a 24-week, randomized, double-blind, parallel-group, placebo-controlled phase, followed by a 32-week, open-label onabotulinumtoxinA treatment phase. The prespecifi ed method of imputation of missing data (ie, <20 days of diary data in a 28-day period) was modifi ed last observation carried forward (mLOCF), which estimated missing data by iteratively multiplying the subject's most recent count by the subsequent average change rate across treatments. We compared mLOCF with last observation carried forward (LOCF), baseline observation carried forward (BOCF), mLOCF withintreatment (mLOCFw), and observed data (without imputation). Simulations to predict known data were analyzed using mLOCF, LOCF, and BOCF. RESULTS: 1384 adults were randomized (PREEMPT1: onabotulinumtoxinA [n = 341], placebo [n = 338]; PREEMPT2: onabotulinumtoxinA [n = 347], placebo [n = 358] ). 1026 (74%) of the subjects had no missing monthly counts during the double-blind phase (PREEMPT1: onabotulinumtoxinA [n = 242], placebo [n = 248]; PREEMPT2: onabotulinumtoxinA [n = 258], placebo [n = 278] ). Each imputation method (mLOCF, LOCF, BOCF, mLOCFw) and observed data generated a similar statistically signifi cant betweengroup difference for the primary effi cacy endpoint of headache-day counts at Week 24 in PREEMPT2 (P < 0.001). Similar results were observed within PREEMPT1 (P < 0.02). Compared to LOCF and BOCF, mLOCF was superior at predicting known values of headache-day counts in simulations that randomly set observed scores to missing, as demonstrated by least-squared errors of imputed minus actual counts. CONCLUSIONS: PREEMPT treatment differences were similar (and statistically signifi cant) using each imputation method, likely due to low dropout rates within each treatment group. Compared to LOCF and BOCF, mLOCF was superior at predicting known data.
SENSORY SYSTEMS DISORDERS -Clinical Outcomes Studies

PSS1
META-ANALYSIS OF PARTIALLY HYDROLYZED 100%-WHEY FORMULA VERSUS EXTENSIVELY HYDROLYZED FORMULAS IN THE PREVENTION OF ATOPIC DERMATITIS
Iskedjian M 1 , Szajewska H 2 , Spieldenner J 3 , Farah B 4 , Berbari J 4 , Navarro V 5 1 PharmIdeas Research and Consulting Inc., Oakville, ON, Canada; 2 Medical University of Warsaw, Warsaw, Poland; 3 Nestlé Nutrition Institute, Vevey, Switzerland; 4 PharmIdeas Research and Consulting Inc., Ottawa, ON, Canada; 5 PharmIdeas Europe SAS, Lyon, France OBJECTIVES: The incidence rates of atopic dermatitis (AD) and relative risks (RR) associated to a brand of partially hydrolyzed 100% whey formula manufactured by Nestlé (PHF-W) and to extensively hydrolyzed formulas (EHF-Whey or Casein) were reported for the prevention of AD in infants who are not exclusively breastfed. METHODS: Szajewska et al. had previously undertaken a meta-analysis determining the incidence rates and RRs of PHF-W compared to cow's milk formula (CMF) and EHF but details were not for provided for PHF-W vs. EHF. This analysis sheds light on the latter comparisons and extends the analyses to 3-month cycles from birth to 36-months of age. Included were any relevant randomized controlled trials comparing the use of PHF-W with CMF or EHF for the prevention of allergies. The primary outcomes of interest were the incidence, cumulative incidence and period prevalence of any allergic manifestations and AD in particular. Of 84 retrieved citations, 15 studies were included for analysis of which 6 studies pertained to PHF-W vs. EHF. All effi cacy data were converted into inputs for a spreadsheet decision-analytic economic model based on 3-month cycles by applying weights derived from the Szajewska et al. meta-analysis and calculating them at 3-month intervals for input into an economic model. RESULTS: The analysis sample included 557, 559 and 580 patients for PHF-W, EHF-Whey and EHF-Casein, respectively. a RR of 0.75 [0.54,1.05] at 0-12 months and 0.80 [0.63,1.02] at 0-36 months was obtained for PHF-W vs. EHF-Whey while a RR of 1.06 [0.74,1.53] at 0-12 months and 1.13 [0.87,1.47] at 0-36 months was determined for PHF-W vs. EHF-Casein. All effi cacy data were adapted into 3-month indicators. CONCLUSIONS: It appears that the effi cacy of PHF-W falls within the range of the other two extensively hydrolyzed formulas.
SENSORY SYSTEMS DISORDERS -Cost Studies
PSS2 USE OF INCREASED DOSAGES OF BIOLOGICS IN PLAQUE PSORIASIS AND POTENTIAL SAVINGS BY TREATING HIGH-DOSE PATIENTS WITH USTEKINUMAB INSTEAD-A BUDGET IMPACT MODEL
Klesse M, Wolbring F Janssen-Cilag GmbH, Neuss, Germany OBJECTIVES: Evaluation of real-life dosing of biologics in plaque psoriasis in Germany and the potential savings by treating patients with ustekinumab instead of using higher doses of TNF-alpha-inhibitors. METHODS: Based on an online survey among 100 dermatologists (DocCheck Medical Services, December 2009) the use of biologics and their dosing distribution for the treatment of plaque psoriasis was evaluated. The proportion of patients receiving maintenance dosages according to label and those receiving a higher dose were evaluated for each biologic separately. a budget impact model was created estimating potential savings by treating patients with ustekinumab according to label (45 mg in patients ≤100 kg body weight and 90 mg in patients >100 kg body weight) instead of high dose TNF-alpha-inhibitors in terms of annual medication costs. In this model, costs of the current usage pattern of biologics were estimated using German pharmacy prices (source: Lauer-Taxe, version June 1, 2010, most economical pack size). RESULTS: In most cases biologic treatments are used according to the respective labels. In some instances, deviating dosages are used: 14% of adalimumab-treated patients receive an increased dosage of 40 mg every week or 80 mg eow, and more than 15% of etanercept-treated patients receive 50 mg twice weekly or another deviating dosage as maintenance therapy. 27% of infl iximabtreated patients receive maintenance injections more frequently than every 8 weeks or receive an increased dosage per injection. In Germany, assuming 80% of those highdose-TNF-alpha-inhibitor-treated patients are treated with ustekinumab instead, this would result in savings of approximately c18 million per year. If induction costs of ustekinumab are considered additionally, still c13 million could be saved within one year. CONCLUSIONS: Using ustekinumab instead of high dosages of TNF-alphainhibitors for treatment of plaque psoriasis can generate signifi cant savings in medication costs in Germany. Severe Chronic Hand Eczema (CHE) can be particularly burdensome. We aimed to assess prevalence, costs and HRQoL in patients with severe CHE. METHODS: A naturalistic, multicentre, epidemiologic and cost-of-illness study is being conducted in 14 Italian dermatological centers. HE patients aged ≥18 years are being enrolled through a 6-month period. The following data are being collected: socio-demographic, clinical (severity, chronicity and responsiveness to treatment with topical potent corticosteroids) and, among chronic, severe and refractory patients, data on HRQol (EQ-5D and the condition specifi c Dermatitis-Life-Quality-Index (DLQI)), direct and indirect costs, from the societal perspective. RESULTS: A preliminary sample of 305 patients (mean age + SD = 41.4 + 14.9, 38.2% male) were enrolled. Two hundred fi fty fi ve patients (83.6%) had CHE and of these the 27.8% were severe. Overall, 20.0% of the enrolled patients were chronic, severe and refractory to therapy. DLQI mean + SD sum score was 10.38 + 5.98. With EQ-5D 92.7% of patients reported moderate or severe pain/discomfort, 70.9% problems with usual activities, 58.2% anxiety/depression and 40% problems with self-care. VAS mean + SD = 61.96 + 21.48. On average hospitalization cost c87.90/patient-month, travels due to CHE cost c69.54/patient-month, specialist visit costs c52.81/patient-month, other products (gloves, gauze bandage, vacuum cleaner, cosmetics) costs c35.70/patient-month, diagnostic exam costs c20.77/patient-month, non pharmacological therapy (emollients, galenic products, soap, UV-ray) cost c15.65/patient-month and pharmacological therapy cost c9.22/patient-month. Patients lost a mean + SD 4.35 + 8.68 workdays/ patient-month for reasons attributable to their condition. CONCLUSIONS: most of the patients in the Italian centers of dermatology have CHE and a fi fth are severe and refractory to therapy. Patients with severe CHE and refractoriness to therapy have poor HRQoL and high costs. a correct diagnosis and treatment is necessary to efficiently manage this condition.
PSS3 EPIDEMIOLOGY, COSTS AND QUALITY OF LIFE IN PATIENT WITH SEVERE CHRONIC HAND ECZEMA
PSS4
COST-OF-ILLNESS IN PATIENTS WITH CHRONIC HAND ECZEMA: RESULTS FROM A MULTI-CENTRE STUDY IN GERMANY
Augustin M 1 , Purwins S 1 , Diepgen T 2 , Posthumus J 3 , Kuessner D 3 1 University Clinics of Hamburg, Hamburg, Germany; 2 University Heidelberg, Heidelberg, Germany; 3 Basilea Pharmaceutica, Basel, Switzerland OBJECTIVES: It is assumed broadly that the costs caused by chronic hand eczema (CHE) are signifi cant. However, there is a lack of cost-of-illness studies on CHE. The objective of this study is, therefore, to determine the direct and indirect costs of chronic hand eczema under routine conditions overall and in different treatment stages in Germany. METHODS: The survey was conducted in 24 outpatient practices and clinics across Germany. Patients with CHE refractory to potent topical treatments and insured by statutory health insurances were eligible. Patient characteristics and resource use were directly gathered from patients and physicians. Costs were evaluated from the societal perspective. Four treatment stages were defi ned: only topical treatments (stage I), additionally photo therapy (II), systemic therapy (III) and inpatient treatment (IV). Bivariate associations between costs and treatment stage were assessed. RESULTS: A total of 223 CHE patients enrolled in the study. The yearly direct and indirect costs per patient are c1742 (SE: c139) and c386 (c83), respectively. a total of 63.2% of patients were treated only with topical treatments; additionally 15.7% with photo therapy, 11.7% with systemic treatments. a total 9.4% of all patients were admitted to hospitals. The total costs increase with treatment stage I-IV (P < 0.001): c1044 (c85), c2307 (c145), c2697 (c461) and c8407 (c991), respectively. Accordingly, costs also correlated with clinical severity. CONCLUSIONS: CHE patients refractory to topical steroids incur marked costs to the society. The costs are increasing disproportionately with escalating treatment stages, especially in patients admitted to hospitals. Hence, new and innovative treatments may help to reduce the societal costs of CHE.
PSS5
COST OF GLAUCOMA IN THE UNITED KINGDOM ACCORDING TO THE UK GPRD
Salmon J 1 , Lafuma A 2 , Robert J 2 , Berdeaux G 3 1 Oxford Eye Hospital, Oxford, UK; 2 CEMKA-EVAL, Bourg la Reine, France; 3 Alcon France, Rueil-Malmaison, France OBJECTIVES: The objective of this analysis was to estimate the total budget dedicated to glaucoma care according to the UKGPRD and to identify factors associated with high costs. METHODS: Data were extracted on patients treated on the National Health Service with a diagnosis of ocular hypertension or glaucoma, or treated with topical intraocular lowering treatment, surgery or laser for glaucoma. The budget was estimated from resources consumed in 2008 and included glaucoma drugs, laser, surgery, hospitalization, specialist and general practitioner (GP) visits. In-patient resources were estimated from the Hospital Episode Statistics. Results were expressed in GBP, 2008. Factors associated with high cost were identifi ed using linear stepwise regression. National extrapolation was performed according to the relative size of the GPRD to the UK general populations. RESULTS: Details of 33,441 patients were extracted, which suggests that about 510,000 patients were treated in the NHS in UK in 2008. The Mean age was 74.2 years, and 47.3% were male. The initial diagnosis was made at 67.8 years. Older patients, longer time since diagnosis, a higher number of previous treatments, a higher number of treatment switches in the previous one year period and use of laser/surgery were associated with a higher annual cost. Spending varied little between regions. Annual drug spending was £91.2 million on inpatient care, £4.4 million on drug prescription renewal (not specifi c to the glaucoma drug). Visits to the GP cost £34.8 million and visits to the eye specialist was >£54.0 million although the latter fi gure is likely to be an under estimate (GPRD underreported eye doctor care). CONCLUSIONS: The 2008 expenditures to care for glaucoma were >£185 million with no regional differences. Three factors were strongly associated with high costs: time since diagnosis, treatment changes, and rescue treatment. This analysis suggests that longer treatment persistence is likely to be associated with cost saving.
PSS6
COST OF ILLNESS OF PSORIASIS-A 1-MONTH PROSPECTIVE STUDY IN SOUTHERN SWEDEN
Ghatnekar O 1 , Ljungberg A 2 , Lundqvist T 2 , Svensson Å 3 , Wirestrand LE 4 1 The Swedish Institute for Health Economics, Lund, Skåne, Sweden; 2 Abbott Scandinavia AB, Solna, Sweden; 3 University of Lund, Malmö, Sweden; 4 Kristianstad Hospital, Kristianstad, Sweden OBJECTIVES: Published cost-of-illness studies of psoriasis in Sweden are not available. This study estimates the societal cost of psoriasis care in a defi ned Swedish patient population. METHODS: A prevalence-based prospective recruitment of patients visiting two dermatology clinics in Sweden between September and December 2009 was performed. Patients collected resource utilization of health care contacts, treatment, travelling distance and time, and productivity loss (human capital approach) during 1 month (Swedish unit prices, 2009) . RESULTS: A total of 164 patients (49% males) were included; average age 52, 76% plaque psoriasis with PASI 5.7, DLQI 7.7 and EQ-5D utility weight 0.71. The mean total cost per patient-month was c994. Main cost drivers were outpatient visits (OP) and light therapy (49%), biological drugs (20%) and productivity loss (22%). When patients were stratifi ed according to treatment strategy, total costs (fraction of patients) for topical treatment only (TT; 34%) was c369, light therapy (LT; 24%) c1274, traditional systemic treatment (TST; 26%) c1085 and biological systemic treatment (BST; 16%) c1709 per patient-month. Main cost drivers in each treatment strategy were: OP (56%) in TT, OP (78%) in LT, productivity loss (40%) in TST and biological drugs (71%) in BST. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. CONCLUSIONS: In this study the cost-of-illness for a psoriasis patient amounts to almost c1000/month, with great variation depending on treatment strategy. Despite the 1200 difference in drug cost for TST vs. BST, total cost per month differed by c600 because of offsets from improved productivity and reductions in OP and topical treatment. As expected, biologically treated patients had higher costs but lower severity probably due to the treatment effectiveness. The relationship between costs and severity is complex, probably due to the selected study period and differences in effect between strategies.
PSS7 THE ECONOMIC COST OF TREATING PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN SPAIN
Darba J 1 , Kaskens L 2 1 Universitat de Barcelona, Barcelona, Spain; 2 BCN Health, Barcelona, Spain OBJECTIVES: Wet macular degeneration associated with age (wet-AMD) is the leading cause of legal blindness in Spain in people over 55. The aim of this study is to determine health care resource utilization and mean costs per patient with wet-AMD in 2009. METHODS: A micro-costing analyses was performed to estimate direct medical costs of patients with wet-AMD. Patient level data was obtained from different public hospitals in Spain and ophthalmologists were surveyed with a semi-structured questionnaire to obtain treatment patterns. Inpatient costs were considered from the perspective of the public health care system. Treatments under study were pegaptanib, verteporfi n, ramibizumab and bavacizumab. Although bevacizumab in Spain is not approved for wet-AMD, it was used off-label in the hospital. Direct medical costs considered were drug costs, administration cost, doctors' visits, nurse time, ophthalmologist time, anaesthetics, ambulant hospital care, external consultation, surgery and treatment of adverse effects. All costs are referred to 2009. RESULTS: Mean cost per patient treated with wet-AMD represented the following cost for the public health care system: c7290 for pegaptanib, c5810c for verteporfi n, c8650 for ramibizumab and c3110 for bevacizumab. We also estimated that in Spain 180,000 people over 50 years have wet-AMD in 2009. CONCLUSIONS: Pharmacological treatments for wet-AMD are photo dynamic therapy with verteporfi n, pegaptanib, verteporfi n and ramibizumab, with the last one having the highest medical costs. The aging of the population and development of new drugs will probably increase the future economic impact of AMD, which remains a major health care burden.
PSS8 PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COST IN GERMANY
Lorenz K 1 , Wolfram C 1 , Claus V 2 , Plesnila-Frank C 2 , Verboven Y 3 , Pfeiffer N 1 1 Universitätsmedizin Mainz, Mainz, Germany; 2 IMS Health, München, Germany; 3 Alcon Research Ltd., Puurs, Belgium OBJECTIVES: To describe total costs and factors predicting cost in Germany for glaucoma disease states: ocular hypertension (OHT), and early (EARLY), moderate (MOD) and advanced (ADV) glaucoma. METHODS: A 5-year retrospective analysis collected health care utilization, clinical parameters, treatment(s) used and reasons for treatment change. Disease states defi ned by the European Glaucoma Society were applied. Costs for health care resources were based upon the German EBM/OPS code for ambulatory visits/procedures, diagnosis-related groups for hospital procedures and the Rote Liste for medication. Factors predicting cost were identifi ed using stepwise backward multiple linear regression, entry criterion a = 0.2. RESULTS: A total of 154 patients (27 OHT, 43 EARLY, 35 MOD, 49 ADV) were enrolled from 15 centers across 5 German regions. Average age was 67 ± 11 and 57% were female. Number of years since diagnosis was 9.0 ± 5.7, 8.7 ± 4.6, 8.7 ± 4.1 and 13.2 ± 8.3 years for OHT, EARLY, MOD and ADV, respectively. Total costs, for patients with OHT, EARLY, MOD or ADV, were c226 ± 117, c423 ± 647, c493 ± 385, and c808 ± 877, respectively. Most costs were due to medication (c121 ± 99, c217 ± 150, c245 ± 161, c340 ± 193) and hospital interventions (c32 ± 101, c115 ± 538, c154 ± 285, c367 ±
